This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
2025 Q1: A Third Look: Discussing the potential of gene therapies in SCD such as Vertex and CRISPR Therapeutics' CASGEVY (Exa-cel) and bluebird bio's LYFGENIA (lovotibeglogene autotemcel).
Ticker(s): VRTX, CRSP, BLUEWho's the expert?
Institution: Penn State Health
- Director of the Pediatric Sickle Cell Program at Penn State Health Children’s Hospital since 2017
- Treats 150 - 200 patients with Alzheimer’s Disease
- Research interest includes movement disorders, biomarkers, Parkinson’s disease, and Alzheimer’s disease.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
